Medulloblastomas Expressing IL13Rα2 are Targets for IL13-zetakine+ Cytolytic T Cells
Authors:
- Christine E. BrownCBChristine E. Brown
- Christopher RuelCRChristopher Ruel
- Michael C. JensenMJMichael C. Jensen
- 1 October 2007
- journal article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 29 (10) , 669-677
Abstract
Central nervous system loco-regional disease relapse is a common etiology of treatment failure for medulloblastoma (MB)/primitive neuroectodermal tumors. Therapeutic targeting of primary disease and the adjacent craniospinal cerebral spinal fluid pathways should decrease relapse rates and allow for the curtailed use of radiation therapy. The adoptive transfer of tumor-specific cytolytic T cells (CTLs) to the tumor bed and cerebral spinal fluid is an attractive strategy, but limited in its clinical application owing to the paucity of defined antigens consistently expressed by these tumors and their potential to escape T-cell recognition by expressing low level surface human leukocyte antigen. Here, we describe the human leukocyte antigen-independent recognition of MB cell-surface IL13Rα2 by genetically modified CTLs expressing an IL13-zetakine chimeric immunoreceptor. We found that IL13-zetakine+ CTLs exhibit potent cytolytic activity toward IL13Rα2+ Daoy cells, and are activated to secrete proinflammatory cytokines such as interferon-γ. By employing an orthotopic NOD-scid murine model in which intraventricularly seeded Daoy cells form tumors on leptomeningeal surfaces, regression of established ffLuc+ Daoy xenografts in response to intraventricularly delivered IL13-zetakine+ CD8+ CTLs was observed using biophotonic imaging. These studies support the rationale for exploring the clinical utility of targeted immunotherapy using adoptively transferred IL13-zetakine redirected CTLs as a therapeutic component for treating IL13Rα2+ MB/primitive neuroectodermal tumors.Keywords
This publication has 32 references indexed in Scilit:
- T-cell genetic modification for re-directed tumor recognition2005
- Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T CellsCancer Research, 2004
- Analysis of interleukin‐13 receptor α2 expression in human pediatric brain tumorsCancer, 2004
- Molecular Expression Analysis of Restrictive Receptor for Interleukin 13, a Brain Tumor-associated Cancer/Testis AntigenMolecular Medicine, 2000
- Primary central nervous system tumors in childrenCurrent Treatment Options in Neurology, 1999
- Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumorsJournal of Neuro-Oncology, 1996
- Primitive neuroectodermal tumors of the central nervous system in childhood: tumor biological aspectsCritical Reviews in Oncology/Hematology, 1994
- Cognitive deficits in long‐term survivors of childhood medulloblastoma and other noncortical tumors: Age‐dependent effects of whole brain radiationInternational Journal of Developmental Neuroscience, 1994
- Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patientsCancer Immunology, Immunotherapy, 1994
- An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK)Acta Neurochirurgica, 1988